These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36765603)

  • 21. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres.
    Kao YH; Steinberg JD; Tay YS; Lim GK; Yan J; Townsend DW; Budgeon CA; Boucek JA; Francis RJ; Cheo TS; Burgmans MC; Irani FG; Lo RH; Tay KH; Tan BS; Chow PKh; Satchithanantham S; Tan AE; Ng DC; Goh AS
    EJNMMI Res; 2013 Jul; 3(1):57. PubMed ID: 23885971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC.
    Veenstra EB; Ruiter SJS; de Haas RJ; Bokkers RPH; de Jong KP; Noordzij W
    EJNMMI Res; 2022 Feb; 12(1):9. PubMed ID: 35122166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer.
    Ridouani F; Soliman MM; England RW; Hsu M; Moskowitz CS; Doustaly R; Sofocleous CT; Boas FE; Yarmohammadi H; Deipolyi AR
    Eur J Radiol; 2021 Mar; 136():109539. PubMed ID: 33476965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative evaluation of
    Kappadath SC; Henry EC; Lopez BP; Mahvash A
    Med Phys; 2024 May; ():. PubMed ID: 38781554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 30. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
    Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma: An Experience With Hybrid Angio-Computed Tomography and Glass Microspheres.
    Baloji A; Kalra N; Chaluvashetty S; Bhujade H; Chandel K; Duseja A; Taneja S; Gorsi U; Kumar R; Singh H; Sood A; Bhattacharya A; Singh B; Mittal BR; Singh V; Sandhu MS
    J Clin Exp Hepatol; 2024; 14(3):101342. PubMed ID: 38283702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Radiation Segmentectomy with
    Sarwar A; Malik MS; Vo NH; Tsai LL; Tahir MM; Curry MP; Catana AM; Bullock AJ; Parker JA; Eckhoff DE; Nasser IA; Weinstein JL; Ahmed M
    Radiology; 2024 May; 311(2):e231386. PubMed ID: 38713023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of SPECT corrections on 3D-dosimetry for liver transarterial radioembolization using the patient relative calibration methodology.
    Pacilio M; Ferrari M; Chiesa C; Lorenzon L; Mira M; Botta F; Becci D; Torres LA; Coca Perez M; Vergara Gil A; Basile C; Ljungberg M; Pani R; Cremonesi M
    Med Phys; 2016 Jul; 43(7):4053. PubMed ID: 27370124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.
    Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A
    J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
    Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
    Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma.
    Orcajo Rincón J; Regi AR; Peña AM; Berenguer LR; Leyte MG; Martín LC; Atance García De La Santa J; Boyra ME; Ruiz CG; Rodríguez AC; Farto JCA
    EJNMMI Phys; 2023 Feb; 10(1):7. PubMed ID: 36745227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.